Market Cap 150.70M
Revenue (ttm) 118.71M
Net Income (ttm) -30.38M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 777.33
Profit Margin -25.59%
Debt to Equity Ratio 0.52
Volume 398,100
Avg Vol 325,594
Day's Range N/A - N/A
Shares Out 6.46M
Stochastic %K 96%
Beta 0.44
Analysts Hold
Price Target $24.43

Company Profile

Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut sy...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 224 419 7106
Fax: 510 744 8001
Address:
100 South Saunders Road, Suite 300, Lake Forest, United States
Polo2024
Polo2024 May. 20 at 2:46 PM
$ASRT No 50% tender vote = PS increase! DON'T TENDER.
0 · Reply
Luckybreak
Luckybreak May. 20 at 1:24 PM
$ASRT Chuckuk What should be our next course of action We the long term retail share holders of SPPI/ASRT and past several years holder of combined ASRT Nice to see management getting rewarded while long term share holders have accumulated an energy’s amount of loss /any which way you look at it .So managment rewarded for selling us short time and again and finally aiming for our jugular
1 · Reply
Chuckuk
Chuckuk May. 20 at 1:07 PM
$ASRT And if Assertio closes with $115M cash, not just $95M, Zydus’s net cost after cash drops to only: $5.70 per share That makes the Party L comparison much more powerful. Party L offered about $26.31 per share for Rolvedon alone, while Zydus’s net cost after minimum cash is only $8.80 per share, or $14.99 including notes.
0 · Reply
Chuckuk
Chuckuk May. 20 at 11:28 AM
$ASRT There is a requiremnt for mores shares to tender and if not the price will have to increase. I believe Zydus has some public exposure reputation 'face' and positive reaction resting on this deal so if they do not get the numbers they will have to raise the tender price. We can see that one of the bids (from bidder L) was $170M for Rolvedon alone leaving the cash and the Cosette portfolio in place that nets out so much higher than the current bid. Also Zydus will have a small reliance on the CVR from Cosette which includes the sale of Indocin which has its own irony! I think they will need, and have the cash, for an increased bid up to $35 plus and even that does not match the offer from bidder L. Hold in my view! Rolvedon is cited as a 'strategic asset' for Zydus.
0 · Reply
Chuckuk
Chuckuk May. 20 at 11:19 AM
$ASRT Zydus shares have strengthened again in India. Economic Times reports Zydus Lifesciences shares rose more than 7% on 20 May 2026, touching a fresh 52-week high of about ₹1,091 on the NSE, helped by Q4 results and the ₹1,100 crore buyback. The market like the transaction. Zydus is openly presenting Assertio/Rolvedon as strategic. Zydus management reportedly described the Assertio acquisition as a “pivotal move” to build a differentiated, high-margin U.S. specialty oncology business, anchored by Rolvedon. They also said the balance sheet gives flexibility to invest further. The 14D-9 still gives shareholders the best squeeze material. It confirms 6,462,180 shares outstanding, $23.50 offer price, and a 15 June 2026 initial expiry. They need many more sshare to tender. The Party L comparison remains the strongest economic attack. The 14D-9 says Party L offered $170M cash for Rolvedon alone, and the Board determined it could reasonably be expected to lead to a Superior Proposal.
2 · Reply
Chuckuk
Chuckuk May. 20 at 6:56 AM
$ASRT Zydus needs to increase its offer to over $35 ie between $35 and $39 in my view for it to be clean and reflect the value of Party L otherwise Zydus will suffer reputational damage and may be part of litigation, not because of their decision but because of the ASRT decision. They are buying Rolvedon for between $60 and $110 Million net plus the Cosette upside CVR. They are at least $11.75 Per share short of the consolidated Party L offer without the upside of Cosette. The Cosette deal was so bad it looks worse than the Rolvedon deal, which has the pessimistic caveats, the only salvation with Cosette is the CVR which SHs NEVER see so possibly Zydus are complicit and they seek to gain from competitor sale of Indocin IS THAT RIGHT OR MORAL? It was Zydus who broke Indocin for Assertio now they can gain from it.
1 · Reply
Chuckuk
Chuckuk May. 20 at 6:38 AM
$ASRT The 14D-9 does mention the categories: tax leakage, severance, contract termination costs, litigation reserves, transaction fees, working-capital wind-down, retirement of the $40M notes, ongoing public-company costs, and a possible multi-year Delaware liquidation process. The weakness is this: they identify the cost categories, but they do not appear to give shareholders a clear per-share bridge showing how $34.82–$39.77 becomes less attractive than $23.50. shareholder question: Provide a detailed per-share reconciliation of the Party L alternative: $170M for Rolvedon, plus closing cash, plus Cosette upfront and deferred consideration/CVR value, less the $40M convertible notes, taxes, transaction fees, severance, reserves, wind-down costs and timing discount. Without that bridge, the Party L alternative appears materially superior to the $23.50 Zydus tender. Party L still looks far superior, unless the Board can show costs/taxes/delay destroyed at least $73M$105M of value.
0 · Reply
Polo2024
Polo2024 May. 20 at 4:14 AM
$ASRT There should be NO SEVERANCE per se. Severance is when you are told to leave the company AFTER YOU HAVE DONE A CONSISTENT GOOD JOB, management is willingly giving it away at shareholders loss for their own benefit.
0 · Reply
Polo2024
Polo2024 May. 19 at 9:38 PM
$ASRT Here is one of the wolves in sheep clothing that has taken our money again and again and going strong for a final steal.
1 · Reply
BigBadBeethoven
BigBadBeethoven May. 19 at 8:17 PM
$ASRT NO OVERBLOWN SEVERANCE!! NO OVERBLOWN GOLDEN PARACHUTES!!! NO OVERBLOWN OPTIONS or anything else for these IDIOTS that did NOTHING but make mistakes from day one and cost us all a lot of money... OUR LOST MONEY THAT IS PAYING FOR MANAGEMENT'S OVERBLOWN SEVERANCE PACKAGES!
1 · Reply
Latest News on ASRT
Assertio, Garda agree to delay launch of tender offer

2026-05-08T17:52:08.000Z - 12 days ago

Assertio, Garda agree to delay launch of tender offer


Assertio Holdings Quarterly report: Q1 2026

May 8, 2026, 7:00 AM EDT - 12 days ago

Assertio Holdings Quarterly report: Q1 2026


Assertio Provides Update on Garda Therapeutics Tender Process

Apr 21, 2026, 5:00 PM EDT - 4 weeks ago

Assertio Provides Update on Garda Therapeutics Tender Process


Assertio downgraded to Hold from Buy at Maxim

2026-04-09T17:35:14.000Z - 5 weeks ago

Assertio downgraded to Hold from Buy at Maxim


Assertio downgraded to Hold from Buy at Lake Street

2026-04-09T13:04:39.000Z - 5 weeks ago

Assertio downgraded to Hold from Buy at Lake Street


Assertio downgraded to Neutral from Buy at H.C. Wainwright

2026-04-09T10:12:06.000Z - 5 weeks ago

Assertio downgraded to Neutral from Buy at H.C. Wainwright


Assertio Holdings Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 6 weeks ago

Assertio Holdings Proxy statement: Proxy filing


Assertio Holdings Earnings Call Transcript: Q4 2025

Mar 16, 2026, 4:30 PM EDT - 2 months ago

Assertio Holdings Earnings Call Transcript: Q4 2025


Assertio Holdings Annual report: Q4 2025

Mar 16, 2026, 4:30 PM EDT - 2 months ago

Assertio Holdings Annual report: Q4 2025


Assertio Holdings Earnings release: Q4 2025

Mar 16, 2026, 4:30 PM EDT - 2 months ago

Assertio Holdings Earnings release: Q4 2025


Assertio regains compliance with Nasdaq listing requirements

2026-01-12T21:21:26.000Z - 4 months ago

Assertio regains compliance with Nasdaq listing requirements


Assertio Therapeutics trading halted, news pending

2025-12-24T21:50:25.000Z - 5 months ago

Assertio Therapeutics trading halted, news pending


Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split

Dec 22, 2025, 4:30 PM EST - 5 months ago

Assertio Holdings, Inc. Announces 1-for-15 Reverse Stock Split


Assertio Holdings Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 6 months ago

Assertio Holdings Earnings Call Transcript: Q3 2025


Assertio Holdings Quarterly report: Q3 2025

Nov 10, 2025, 4:30 PM EST - 6 months ago

Assertio Holdings Quarterly report: Q3 2025


Assertio Holdings Earnings release: Q3 2025

Nov 10, 2025, 4:30 PM EST - 6 months ago

Assertio Holdings Earnings release: Q3 2025


Assertio Reports Third Quarter 2025 Financial Results

Nov 10, 2025, 4:13 PM EST - 6 months ago

Assertio Reports Third Quarter 2025 Financial Results


Assertio Announces Leadership Transition

Oct 28, 2025, 9:15 AM EDT - 7 months ago

Assertio Announces Leadership Transition


Assertio Holdings Earnings Call Transcript: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 10 months ago

Assertio Holdings Earnings Call Transcript: Q2 2025


Assertio Holdings Quarterly report: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 10 months ago

Assertio Holdings Quarterly report: Q2 2025


Assertio Holdings Earnings release: Q2 2025

Aug 11, 2025, 4:30 PM EDT - 10 months ago

Assertio Holdings Earnings release: Q2 2025


Assertio Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:05 PM EDT - 10 months ago

Assertio Reports Second Quarter 2025 Financial Results


Assertio Holdings Slides: Corporate Presentation

May 21, 2025, 7:00 AM EDT - 1 year ago

Assertio Holdings Slides: Corporate Presentation


Assertio Holdings Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Assertio Holdings Earnings Call Transcript: Q1 2025


Assertio Holdings Quarterly report: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Assertio Holdings Quarterly report: Q1 2025


Assertio Holdings Earnings release: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Assertio Holdings Earnings release: Q1 2025


Assertio Reports First Quarter 2025 Financial Results

May 12, 2025, 4:01 PM EDT - 1 year ago

Assertio Reports First Quarter 2025 Financial Results


Assertio Holdings Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Assertio Holdings Proxy statement: Proxy Filing


Assertio Holdings Proxy statement: Proxy Filing

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Assertio Holdings Proxy statement: Proxy Filing


Assertio Holdings Earnings Call Transcript: Q4 2024

Mar 12, 2025, 4:30 PM EDT - 1 year ago

Assertio Holdings Earnings Call Transcript: Q4 2024


Assertio Holdings Annual report: Q4 2024

Mar 12, 2025, 4:30 PM EDT - 1 year ago

Assertio Holdings Annual report: Q4 2024


Assertio Holdings Earnings release: Q4 2024

Mar 12, 2025, 4:30 PM EDT - 1 year ago

Assertio Holdings Earnings release: Q4 2024


Assertio Holdings Earnings Call Transcript: Q3 2024

Nov 11, 2024, 4:30 PM EST - 1 year ago

Assertio Holdings Earnings Call Transcript: Q3 2024


Assertio Holdings Quarterly report: Q3 2024

Nov 11, 2024, 4:30 PM EST - 1 year ago

Assertio Holdings Quarterly report: Q3 2024


Assertio Holdings Earnings release: Q3 2024

Nov 11, 2024, 4:30 PM EST - 1 year ago

Assertio Holdings Earnings release: Q3 2024


Assertio Reports Third Quarter 2024 Financial Results

Nov 11, 2024, 4:02 PM EST - 1 year ago

Assertio Reports Third Quarter 2024 Financial Results


Assertio Provides Response to Letter from Short-seller

Nov 11, 2024, 7:30 AM EST - 1 year ago

Assertio Provides Response to Letter from Short-seller


Assertio Holdings Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Assertio Holdings Earnings Call Transcript: Q2 2024


Assertio Holdings Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Assertio Holdings Quarterly report: Q2 2024


Assertio Reports Second Quarter 2024 Financial Results

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Assertio Reports Second Quarter 2024 Financial Results


Polo2024
Polo2024 May. 20 at 2:46 PM
$ASRT No 50% tender vote = PS increase! DON'T TENDER.
0 · Reply
Luckybreak
Luckybreak May. 20 at 1:24 PM
$ASRT Chuckuk What should be our next course of action We the long term retail share holders of SPPI/ASRT and past several years holder of combined ASRT Nice to see management getting rewarded while long term share holders have accumulated an energy’s amount of loss /any which way you look at it .So managment rewarded for selling us short time and again and finally aiming for our jugular
1 · Reply
Chuckuk
Chuckuk May. 20 at 1:07 PM
$ASRT And if Assertio closes with $115M cash, not just $95M, Zydus’s net cost after cash drops to only: $5.70 per share That makes the Party L comparison much more powerful. Party L offered about $26.31 per share for Rolvedon alone, while Zydus’s net cost after minimum cash is only $8.80 per share, or $14.99 including notes.
0 · Reply
Chuckuk
Chuckuk May. 20 at 11:28 AM
$ASRT There is a requiremnt for mores shares to tender and if not the price will have to increase. I believe Zydus has some public exposure reputation 'face' and positive reaction resting on this deal so if they do not get the numbers they will have to raise the tender price. We can see that one of the bids (from bidder L) was $170M for Rolvedon alone leaving the cash and the Cosette portfolio in place that nets out so much higher than the current bid. Also Zydus will have a small reliance on the CVR from Cosette which includes the sale of Indocin which has its own irony! I think they will need, and have the cash, for an increased bid up to $35 plus and even that does not match the offer from bidder L. Hold in my view! Rolvedon is cited as a 'strategic asset' for Zydus.
0 · Reply
Chuckuk
Chuckuk May. 20 at 11:19 AM
$ASRT Zydus shares have strengthened again in India. Economic Times reports Zydus Lifesciences shares rose more than 7% on 20 May 2026, touching a fresh 52-week high of about ₹1,091 on the NSE, helped by Q4 results and the ₹1,100 crore buyback. The market like the transaction. Zydus is openly presenting Assertio/Rolvedon as strategic. Zydus management reportedly described the Assertio acquisition as a “pivotal move” to build a differentiated, high-margin U.S. specialty oncology business, anchored by Rolvedon. They also said the balance sheet gives flexibility to invest further. The 14D-9 still gives shareholders the best squeeze material. It confirms 6,462,180 shares outstanding, $23.50 offer price, and a 15 June 2026 initial expiry. They need many more sshare to tender. The Party L comparison remains the strongest economic attack. The 14D-9 says Party L offered $170M cash for Rolvedon alone, and the Board determined it could reasonably be expected to lead to a Superior Proposal.
2 · Reply
Chuckuk
Chuckuk May. 20 at 6:56 AM
$ASRT Zydus needs to increase its offer to over $35 ie between $35 and $39 in my view for it to be clean and reflect the value of Party L otherwise Zydus will suffer reputational damage and may be part of litigation, not because of their decision but because of the ASRT decision. They are buying Rolvedon for between $60 and $110 Million net plus the Cosette upside CVR. They are at least $11.75 Per share short of the consolidated Party L offer without the upside of Cosette. The Cosette deal was so bad it looks worse than the Rolvedon deal, which has the pessimistic caveats, the only salvation with Cosette is the CVR which SHs NEVER see so possibly Zydus are complicit and they seek to gain from competitor sale of Indocin IS THAT RIGHT OR MORAL? It was Zydus who broke Indocin for Assertio now they can gain from it.
1 · Reply
Chuckuk
Chuckuk May. 20 at 6:38 AM
$ASRT The 14D-9 does mention the categories: tax leakage, severance, contract termination costs, litigation reserves, transaction fees, working-capital wind-down, retirement of the $40M notes, ongoing public-company costs, and a possible multi-year Delaware liquidation process. The weakness is this: they identify the cost categories, but they do not appear to give shareholders a clear per-share bridge showing how $34.82–$39.77 becomes less attractive than $23.50. shareholder question: Provide a detailed per-share reconciliation of the Party L alternative: $170M for Rolvedon, plus closing cash, plus Cosette upfront and deferred consideration/CVR value, less the $40M convertible notes, taxes, transaction fees, severance, reserves, wind-down costs and timing discount. Without that bridge, the Party L alternative appears materially superior to the $23.50 Zydus tender. Party L still looks far superior, unless the Board can show costs/taxes/delay destroyed at least $73M$105M of value.
0 · Reply
Polo2024
Polo2024 May. 20 at 4:14 AM
$ASRT There should be NO SEVERANCE per se. Severance is when you are told to leave the company AFTER YOU HAVE DONE A CONSISTENT GOOD JOB, management is willingly giving it away at shareholders loss for their own benefit.
0 · Reply
Polo2024
Polo2024 May. 19 at 9:38 PM
$ASRT Here is one of the wolves in sheep clothing that has taken our money again and again and going strong for a final steal.
1 · Reply
BigBadBeethoven
BigBadBeethoven May. 19 at 8:17 PM
$ASRT NO OVERBLOWN SEVERANCE!! NO OVERBLOWN GOLDEN PARACHUTES!!! NO OVERBLOWN OPTIONS or anything else for these IDIOTS that did NOTHING but make mistakes from day one and cost us all a lot of money... OUR LOST MONEY THAT IS PAYING FOR MANAGEMENT'S OVERBLOWN SEVERANCE PACKAGES!
1 · Reply
BigBadBeethoven
BigBadBeethoven May. 19 at 8:11 PM
$ASRT Methinks something is ROTTEN in the STATE (of Affairs) of (if not DENMARK then certainly) ASRT
0 · Reply
BigBadBeethoven
BigBadBeethoven May. 19 at 8:04 PM
$ASRT . 666.....666.... An appropriate figure for how much we were up today given the 1 for 15 reverse split..... 666 of a penny indeed. Perfect figure for ASRT management that is so stupid.... and possibly CRIMINAL .... in such BIBLICAL proportions .666
0 · Reply
Pitulolo
Pitulolo May. 19 at 5:03 PM
$ASRT ruin at these prices
0 · Reply
Chuckuk
Chuckuk May. 19 at 5:09 AM
$ASRT Party L looks like the best economic route on paper: it offered $165M$170M for Rolvedon alone, leaving Assertio’s cash, non-Rolvedon assets and Cosette milestone rights available for shareholders. Zydus is the best clean whole-company offer, but at $23.50 it looks low once you net off the $95M+ cash and consider retained Cosette upside. Garda’s final $23.60 plus CVR was nominally higher, but the Board preferred Zydus for certainty. The Cosette sale looks weakest unless its value was fully credited in the takeover price. The core challenge is that the Board relies on severe Rolvedon pessimism after 2027, despite patent/exclusivity protection and prior Rolvedon-only bids. The best proposal is a higher Zydus offer: ideally $30$32 cash plus a CVR, paying up to $10 if Rolvedon beats management’s projected 2028–2029 revenue and EBITDA decline.
0 · Reply
Polo2024
Polo2024 May. 19 at 3:16 AM
$ASRT ASRT Management has prioritized their retirement and payouts, lets apply real world common sense to the table below. No much working life left for management starting at the top. These payouts are paramount to them, whatever deal has the most $$ for them they'll favor. They have omitted, concealed and managed information in a very unethical manner. Unfortunately they have too much experience dodging the bullet with law suits and they can estimate the damage of their deeds which at the end will be peanuts at best if we join forces and win a litigation and they don't have to pay from their pockets anyways if they lose a litigation, is US who pay it all. I think they are threading carefully to not get caught blatantly with their hands in the cookie jar (more like crooked arms and legs in the jar). This is what we are dealing with after supporting the business with our hard earned money. Price $35-$37 per share no vote if less.
1 · Reply
Chuckuk
Chuckuk May. 19 at 2:24 AM
$ASRT KEEP UP THE PRESSURE
0 · Reply
Chuckuk
Chuckuk May. 19 at 2:21 AM
$ASRT Party L offered £170M Zydus is offering net $100M less $13 per share so there really must be another $8-10 in it now hence the $32 and then hedging the pessimistic Board view a CVR of $10 per share tendered based on revenue and EBITDA targets payable 2028 - 2030
2 · Reply
Chuckuk
Chuckuk May. 19 at 2:03 AM
$ASRT Put simply $32 per share cash, or at minimum a materially increased cash price plus a CVR that pays shareholders if Rolvedon outperforms the Board’s 2028–2029 downside projections. The most persuasive version is not “we want $42.” It is: “The Board is asking shareholders to accept a price justified by severe Rolvedon pessimism. If that pessimism is correct, a CVR costs Zydus little. If it is wrong, shareholders should participate in the upside they are being asked to surrender.” That is a strong and rational shareholder position and one I believe Zydus could smash out of the park!
0 · Reply
Chuckuk
Chuckuk May. 19 at 1:35 AM
$ASRT handled differently this was between $30 and $45 per share value but the decision to protect professional reputations and a quick definite payout for the Senior Team seemed to be paramount in the decision process not that of SH value Rolvedon and Revlon may have more than just letters in common. We should not settle for anything less than a mid point offer of $37 but, after the unevidenced dire projection of Rolvedon revenue post 2027, that seems a tough squeeze how tested is that projection? Maybe $10 plus should be a CVR style recompense based on revenue proving the Board's projections wrong. So, on balance a fair offer would be $32 per share now plus a $10 CVR based on 2028 revenue EBITDA and projections, in my view of course. At least Rolvedon sales will be visible and not in a Private Company but operated by a fantastic World power in Pharma who, if anyone can, Zydus can.
0 · Reply
Chuckuk
Chuckuk May. 19 at 1:19 AM
$ASRT Please show the quantitative bridge from Party L’s $165M$170M Rolvedon proposal, plus cash and non-Rolvedon value, to the Board’s conclusion that $23.50 Zydus was superior. Please itemise tax, severance, adviser fees, break fees, note treatment, litigation reserves, wind-down costs, timing discount and public-company costs. Please also explain how the Board weighed those deductions against management’s own change-of-control benefits and the professional preference for avoiding a multi-year liquidation. Break-up route Rough net pot before tax/wind-down leakage Approx. value per current common share Party L $165M Rolvedon + Q1 cash/investments $71.6M - $40M notes $196.6M $30.42/share Same, plus $35M non-Rolvedon sale $231.6M $35.84/share Party L $165M + assumed $100M cash - $40M notes $225.0M $34.82/share Party L $165M + $100M cash + $35M non-Rolvedon sale - notes $260.0M $40.24/share Party L later $170M + $100M cash + possible $67M Cosette economics - notes $297.0M $45.96/share
1 · Reply
Chuckuk
Chuckuk May. 19 at 1:10 AM
$ASRT The 14D-9 lists many deductions from a Rolvedon-only asset sale, including taxes, severance, litigation reserves, transaction fees, note repayment, wind-down costs and timing discount. Please provide the Board’s actual quantitative deduction schedule showing how Party L’s $165M$170M Rolvedon proposal, combined with Assertio’s cash and non-Rolvedon asset value, produced less distributable value than the $23.50 Zydus offer. Please also explain how the Board weighed this against management’s change-of-control payments, accelerated equity cash-outs, adviser fees and the interests of public shareholders. That is strong, fair, and difficult to dismiss.
0 · Reply
Chuckuk
Chuckuk May. 19 at 1:06 AM
$ASRT Ok some true meat on the dubiously calculated bones; Party L made a $170M offer for Rolvedon leaving everything else in place including cash. If Party L’s $165M$170M Rolvedon proposal had been accepted, Assertio could have retained cash and separately sold the non-Rolvedon assets. Even after deducting the $40M notes, rough gross value could have been in the $30$40+ per share range before tax and wind-down deductions. The 14D-9 does not appear to provide a quantified bridge explaining why that alternative was inferior to $23.50 cash. The question I would put to the Board or counsel. The issue is not whether the break-up value was definitely $40. It is that shareholders deserve to see the Board’s actual deduction schedule: tax, severance, fees, reserves, wind-down provider cost, timing discount and note treatment even so is it because the Boards and management's earn out is better? Who was uppermost in the Board's mind SHs or Board and Mngmt???
0 · Reply